06:31 AM EDT, 07/10/2025 (MT Newswires) -- Soleno Therapeutics ( SLNO ) reported Thursday Q2 preliminary net revenue from sales of Vykat Xr to be between $31 million and $33 million.

As of June 30, Soleno had about $293.8 million in preliminary cash, cash equivalents and marketable securities.

Soleno said it continues to have about $50 million of debt outstanding under its loan and security deal with Oxford Financing at the end of Q2.

Shares of the company were down more than 7% in recent Thursday premarket activity.

Price: 82.00, Change: -6.49, Percent Change: -7.33